ZNF582 and gastric cancer: Peng et al., 2022 developed a panel combining ZNF582, ELMO1, and TFPI2, which allowed for the simultaneous detection of GC, EC, and esophagogastric junction cancer (EJC), with a sensitivity of 79.2% for EC and a specificity of 90.0%. In 2023, Dai et al., 2023 developed a 6-marker panel (KCNQ5, C9orf50, CLIP4, ELMO1, ZNF582 and TFPI2) to detect of EC, GC and CRC, it achieved sensitivities for detecting EC of 64.7% and 83.35 in training and validation sets with specificities of 94.1% and 86.7%.